Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 40.65B | 34.07B | 31.97B | 27.77B | 19.42B |
Gross Profit | 4.74B | 4.33B | 3.93B | 3.28B | 2.68B |
EBITDA | 1.89B | 1.74B | 1.35B | 1.13B | 1.15B |
Net Income | 1.18B | 1.09B | 792.00M | 659.00M | 673.00M |
Balance Sheet | |||||
Total Assets | 15.63B | 14.89B | 12.31B | 12.21B | 9.53B |
Cash, Cash Equivalents and Short-Term Investments | 8.99B | 9.11B | 7.50B | 7.64B | 6.03B |
Total Debt | 3.12B | 2.38B | 2.39B | 2.39B | 2.35B |
Total Liabilities | 11.13B | 10.68B | 9.35B | 9.58B | 7.44B |
Stockholders Equity | 4.50B | 4.21B | 2.96B | 2.63B | 2.10B |
Cash Flow | |||||
Free Cash Flow | 544.00M | 1.58B | 682.00M | 2.04B | 1.82B |
Operating Cash Flow | 644.00M | 1.66B | 773.00M | 2.12B | 1.89B |
Investing Cash Flow | -464.00M | -744.00M | -790.00M | -1.65B | -400.00M |
Financing Cash Flow | -347.00M | -58.00M | -441.00M | -183.00M | 225.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $27.66B | 16.77 | 10.09% | 1.54% | 10.09% | -12.18% | |
72 Outperform | $14.64B | 4.38 | 12.59% | ― | 8.85% | 33.30% | |
72 Outperform | $78.24B | 14.77 | 7.00% | 4.53% | 4.84% | -26.54% | |
68 Neutral | $81.30B | 16.86 | 12.37% | 1.98% | 24.65% | 48.38% | |
67 Neutral | $66.79B | 12.62 | 12.48% | 2.38% | 10.21% | -17.79% | |
66 Neutral | CHF27.76B | 14.92 | 9.37% | 1.98% | 28.68% | 7.54% | |
63 Neutral | $9.79B | 8.73 | 23.93% | ― | 16.12% | 10.99% |
On April 30, 2025, Molina Healthcare held its Annual Meeting where 85.6% of the company’s outstanding shares were represented. During the meeting, stockholders voted on several proposals, including the election of nine directors, approval of executive compensation, ratification of Ernst & Young LLP as the independent auditor, approval of the 2025 Equity Incentive Plan, and a stockholder proposal regarding special meetings. Key outcomes included the election of directors and the approval of the equity plan, while the executive compensation proposal faced significant opposition.